Interstitial Lung Disease: Definition, Diagnostics, and Management
Definition
Interstitial lung disease (ILD) encompasses a heterogeneous group of over 300 pulmonary disorders characterized by inflammation and/or fibrosis of the lung parenchyma, resulting in impaired gas exchange, progressive dyspnea, and reduced quality of life. 1, 2
ILD is classified into several major categories 1:
- Idiopathic interstitial pneumonias (IIPs) - accounting for approximately 55% of cases, with idiopathic pulmonary fibrosis (IPF) being the most common and severe form 1
- Known causes - including drug toxicity, environmental exposures, and collagen vascular diseases 1
- Granulomatous lung diseases - such as sarcoidosis 1
- Connective tissue disease-associated ILD (CTD-ILD) - accounting for approximately 25% of cases 2
- Hypersensitivity pneumonitis - representing about 15% of ILD cases 2
The most clinically significant subtypes include IPF (one-third of all ILD cases), nonspecific interstitial pneumonia (NSIP), respiratory bronchiolitis-associated ILD, cryptogenic organizing pneumonia, acute interstitial pneumonia, desquamative interstitial pneumonia, and lymphoid interstitial pneumonia 1.
Diagnostic Approach
Clinical Presentation
ILD typically presents with insidious onset of exertional dyspnea in adults, most commonly in the sixth and seventh decades of life, accompanied by bibasilar inspiratory crackles on examination. 1
Key clinical features to identify 1:
- Dyspnea on exertion - the hallmark symptom present in nearly all patients 1
- Nonproductive cough - reported in approximately 30% of patients 1, 2
- Bibasilar inspiratory crackles - dry or "Velcro-type" quality on auscultation 1
- Digital clubbing - may be present, particularly in IPF 1
- Duration of symptoms - typically greater than 3 months for chronic forms 1
Critical exclusion criteria: Rule out known causes including drug toxicities, environmental exposures (occupational, allergens, toxins), and connective tissue diseases through detailed history 1, 3.
High-Resolution Computed Tomography (HRCT)
HRCT has a central and mandatory role in the diagnostic pathway, with approximately 91% sensitivity and 71% specificity for diagnosing ILD subtypes. 1, 2
Volumetric chest CT scanning is the standard technique, as it improves detection of subtle or focal abnormalities compared to sequential scanning. 1
HRCT Pattern Recognition for IPF Diagnosis 1:
UIP Pattern (definite IPF diagnosis without biopsy):
- Subpleural and basal predominant distribution
- Reticular opacities with honeycombing
- Traction bronchiectasis and bronchiolectasis
- Absence of features inconsistent with UIP (ground-glass opacities, nodules, consolidation)
Probable UIP Pattern:
- Reticular abnormalities with traction bronchiectasis
- May have mild ground-glass opacities
- Absence of honeycombing
Indeterminate for UIP:
- Subtle reticulation without other defining features
- Requires further diagnostic workup
Alternative Diagnosis:
- Features suggesting other ILD subtypes (e.g., fibrotic NSIP, hypersensitivity pneumonitis)
Common pitfall: HRCT misdiagnosis occurs particularly with less experienced radiologists, emphasizing the need for expert interpretation 1.
Pulmonary Function Testing
Comprehensive pulmonary function testing with gas exchange analysis is obligatory for all suspected ILD cases. 1, 3
Key parameters to assess 1, 2, 3:
- Forced vital capacity (FVC) - typically reduced, indicating restrictive physiology
- FEV1/FVC ratio - often increased due to preserved FEV1 relative to reduced FVC
- Total lung capacity (TLC) - reduced in restrictive disease
- Diffusing capacity for carbon monoxide (DLCO) - impaired, reflecting gas exchange abnormality
- Arterial blood gas analysis - increased alveolar-arterial oxygen gradient at rest or with exercise
Prognostic significance: A 5% decline in FVC over 12 months is associated with approximately 2-fold increase in mortality and defines progressive disease 2.
Multidisciplinary Discussion (MDD)
An integrated multidisciplinary approach involving pulmonologists, radiologists, and pathologists is mandatory for accurate ILD diagnosis and classification. 1, 4
The MDD should integrate 1, 4:
- Clinical features and exposure history
- HRCT patterns
- Pulmonary function trends
- Histopathology (when available)
- Serologic testing results
Surgical Lung Biopsy
Surgical lung biopsy (via video-assisted thoracoscopy or open thoracotomy) is recommended when HRCT shows probable UIP, indeterminate, or alternative diagnosis patterns, provided there are no contraindications to surgery. 1
In the correct clinical context, a definite UIP pattern on HRCT negates the need for surgical lung biopsy. 1
Biopsy considerations 1:
- Multiple samples from different lobes improve diagnostic yield
- Avoid areas of advanced honeycombing (end-stage fibrosis)
- Histopathologic UIP pattern confirms IPF diagnosis when clinical and radiologic features are consistent
Bronchoalveolar Lavage (BAL)
The diagnostic role of BAL in IPF remains limited and controversial, primarily serving to exclude alternative diagnoses rather than confirm IPF. 1
BAL may be useful to 1:
- Exclude infection, malignancy, or eosinophilic pneumonia
- Identify hypersensitivity pneumonitis (lymphocytosis)
- Rule out alveolar hemorrhage or proteinosis
BAL is not recommended as a standalone diagnostic test for IPF. 1
Laboratory Testing
Serologic testing is essential to exclude CTD-ILD and identify systemic disease associations. 1, 3
Recommended laboratory workup 1, 3:
- Antinuclear antibodies (ANA)
- Rheumatoid factor (RF)
- Anti-cyclic citrullinated peptide (anti-CCP) antibodies
- Anti-topoisomerase (Scl-70) for systemic sclerosis
- Myositis-specific antibodies (including antisynthetase antibodies)
- Complete blood count, comprehensive metabolic panel
- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
Management Strategies
Pharmacological Treatment
Idiopathic Pulmonary Fibrosis
Antifibrotic therapy with nintedanib or pirfenidone is the first-line treatment for IPF, slowing annual FVC decline by approximately 44-57%. 2, 5
Both agents have similar efficacy and should be initiated at diagnosis or first identification of clinical/physiological impairment. 2, 5
- Nintedanib: Tyrosine kinase inhibitor targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors 2
- Pirfenidone: Anti-inflammatory and antifibrotic properties through multiple mechanisms 2, 5
Common pitfall: Delaying antifibrotic therapy until significant functional decline occurs reduces treatment effectiveness 2.
Connective Tissue Disease-Associated ILD
Immunomodulatory therapy is the cornerstone of CTD-ILD management, with mycophenolate mofetil as first-line treatment for most CTD-ILD subtypes. 2, 6, 7
Disease-specific recommendations 2, 6, 7:
Systemic sclerosis-ILD:
- Mycophenolate mofetil (first-line)
- Tocilizumab (for progressive disease)
- Nintedanib (antifibrotic option)
Rheumatoid arthritis-ILD:
- Mycophenolate mofetil or rituximab
- Avoid methotrexate in established RA-ILD
Idiopathic inflammatory myopathy-ILD:
- Mycophenolate mofetil combined with corticosteroids
- Rituximab for refractory cases
Sjögren disease and SLE-ILD:
- Mycophenolate mofetil
- Cyclophosphamide for severe or rapidly progressive disease
Evidence gap: Insufficient evidence exists for pirfenidone in CTD-ILD other than RA-ILD 6, 7.
Non-Pharmacological Interventions
Pulmonary Rehabilitation
Structured exercise therapy is strongly recommended for all ILD patients with dyspnea, as it reduces symptoms and improves 6-minute walk test distance and quality of life. 2, 5
Components include 2:
- Supervised aerobic exercise training
- Strength training
- Breathing techniques
- Education and self-management strategies
Supplemental Oxygen
Oxygen therapy is indicated for patients who desaturate below 88% on 6-minute walk test, as it reduces symptoms and improves quality of life. 2
Oxygen prescription criteria 2:
- Resting hypoxemia (PaO2 <55 mmHg or SpO2 <88%)
- Exercise-induced desaturation below 88%
- Nocturnal desaturation
Lung Transplantation
Lung transplantation should be considered for patients with advanced ILD who meet established criteria, as it improves median survival from less than 2 years to 5.2-6.7 years post-transplant. 2, 5
Referral timing 2:
- FVC <80% predicted or DLCO <40% predicted
- Decline in FVC ≥10% over 6 months
- Oxygen requirement at rest
- Pulmonary hypertension development
Early referral to transplant centers is critical, as evaluation and listing processes are lengthy. 2
Management of Complications
Pulmonary Hypertension
Up to 85% of patients with end-stage fibrotic ILD develop pulmonary hypertension, which significantly worsens prognosis. 2, 8
For ILD-associated pulmonary hypertension, inhaled treprostinil improves walking distance and respiratory symptoms. 2, 8
Diagnostic approach for ILD-PH 8:
- Echocardiographic screening (elevated right ventricular systolic pressure)
- Right heart catheterization for confirmation (mean pulmonary artery pressure ≥20 mmHg)
- Exclude left heart disease and thromboembolic disease
Caution: Other pulmonary vasodilators have limited evidence in ILD-PH and may worsen gas exchange through ventilation-perfusion mismatch 8.
Acute Exacerbations
Acute exacerbations represent unexplained worsening of dyspnea over days to weeks with new ground-glass opacification on HRCT, carrying high mortality. 1
Management approach 1:
- High-dose corticosteroids (methylprednisolone 500-1000 mg/day for 3 days)
- Exclude infection, heart failure, and pulmonary embolism
- Supportive care with mechanical ventilation if needed
- Consider lung transplant evaluation for survivors
Monitoring and Follow-Up
Serial monitoring should combine clinical assessment, pulmonary function testing, and imaging to detect disease progression. 1, 6, 7
Recommended monitoring schedule 1, 6, 7:
- Every 3-6 months: Clinical evaluation, pulmonary function tests (FVC, DLCO), 6-minute walk test
- Every 6-12 months: HRCT imaging (more frequently if progressive disease suspected)
- As needed: Oxygen saturation assessment, echocardiography for pulmonary hypertension screening
Progressive pulmonary fibrosis criteria (any of the following over 12 months) 1:
- Relative decline in FVC ≥10% predicted
- Relative decline in DLCO ≥15% predicted
- Worsening respiratory symptoms with radiologic progression
- Increased extent of fibrosis on HRCT
Risk Stratification and Prognosis
IPF carries the worst prognosis among ILDs, with 5-year survival worse than several cancers and significantly lower than other ILD subtypes. 1, 9
Comparative survival data 9:
- IPF: Mean survival 33.6 months
- CTD-ILD overall: Mean survival 56.0 months
- Antisynthetase syndrome: 58.2 months with potential functional improvement
- Dermatomyositis-ILD: 52.9 months with potential functional improvement
- Systemic sclerosis-ILD: 55.2 months
Prognostic factors associated with worse outcomes include older age, male sex, UIP pattern on imaging/histology, and baseline functional impairment. 1, 9
For CTD-ILD, the underlying diagnosis is the primary determinant of functional trajectory and prognosis, rather than the radiologic pattern alone. 9